CAR-Modified T Cells Directed Against CD19 in Relapsed/Refractory CLL


CAR-Modified T Cells Directed Against CD19 in Relapsed/Refractory CLL
Slides from presentations at ASH 2013 and transcribed comments from a recent interview with David L Porter, MD (3/3/14)
Porter DL et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Proc ASH 2013;Abstract 873.

Porter DL et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. Proc ASH 2013;Abstract 4162.

Dr Porter is Jodi Fisher Horowitz Professor of Leukemia Care Excellence and Director of Blood and Marrow Transplantation at the University of Pennsylvania Health System's Abramson Cancer Center in Philadelphia, Pennsylvania.